Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.
News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.
Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.
This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Mustang Bio, Inc. (Nasdaq: MBIO) announced a 15-for-1 reverse stock split effective April 4, 2023, to comply with Nasdaq’s $1.00 minimum bid price requirement. This approval came from the Board of Directors and stockholders representing approximately 62.2% of voting power. The outstanding shares will decrease from approximately 109.4 million to about 7.3 million. Stockholders will not receive fractional shares but will instead receive a cash payment. Mustang continues to focus on cell and gene therapies targeting hematologic cancers and genetic diseases.
Mustang Bio, Inc. (Nasdaq: MBIO) reported its financial results and corporate highlights for the year ended December 31, 2022. The company focuses on cell and gene therapies, particularly its leading candidate MB-106 for treating B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. MB-106 has demonstrated a 96% overall response rate and a 75% complete response rate in trials. Financially, Mustang's cash position declined to $76.7 million from $110.6 million year-over-year. The net loss for 2022 was $77.5 million, or $0.75 per share. The company aims to disclose additional data from ongoing trials in 2023, supporting an accelerated approval strategy for key indications.
Mustang Bio, Inc. (Nasdaq: MBIO) announced that its CEO, Manuel Litchman, will participate in Cantor's The Future of Oncology Virtual Symposium. The panel discussion titled “CAR-Ts in Hematological Malignancies” is scheduled for April 3, 2023, at 12:00 p.m. ET. Mustang Bio focuses on cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company aims to enhance its R&D through strategic partnerships and licensing agreements. Mustang's innovative therapies are developed in collaboration with leading medical institutions, reinforcing its commitment to advancing healthcare solutions.
Mustang Bio, Inc. (Nasdaq: MBIO) announced that its President and CEO, Manuel Litchman, M.D., will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 3:00 p.m. EST. The conference will showcase over 30 SMiD cap healthcare companies and discuss advancements in immunotherapy, cell therapy, and oncology. Additionally, a replay of the session will be available post-event. Mustang is focused on developing cell and gene therapies for hematologic cancers and rare genetic diseases, aiming for potential cures through collaborations with leading medical institutions.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
